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Pituitary metastasis is an unusual event of cancer progression and breast cancer is the most common
primary neoplasm metastasizing to the pituitary in the female population. Most patients who have
developed pituitary metastasis were clinically asymptomatic. However, it is difﬁcult to diagnose pituitary
metastases due to the lack of speciﬁc symptomatology. We herein describe the presentation of one
patient with symptomatic pituitary metastasis resulting from primary breast cancer. Subsequent to
surgical intervention and loco-regional radiotherapy, the patient had a favorable outcome.
Copyright © 2016, The Chinese Oncology Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pituitary metastasis is an unusual event of cancer progression.
Approximately 30% of pituitary metastasis cases originate from
primary breast cancer,1 and the prognosis of breast cancer with
pituitary metastasis is poor. According to earlier studies, most pa-
tients have clinical and/or radiologic evidence of widespread dis-
ease at the time they are diagnosed with pituitary metastasis.2,3
Here, we presented a case of solitary pituitary metastasis from
primary breast cancer.
2. Case report
A 60-year-old female with bilateral hemianopsia was admitted
for treatment at the Mackay Memorial Hospital in October, 2013. In
1998 she had been diagnosed with left breast cancer and was
treated with modiﬁed radical mastectomy. Pathology revealed
inﬁltrating ductal carcinoma of pT3N0M0, which was estrogenSurgery, Mackay Memorial
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Society. Production and hosting byreceptor positive, progesterone receptor positive, and HER2-
negative. Six cycles of adjuvant chemotherapy with cyclophos-
phamide, and methotrexate plus ﬂuorouracil (CMF) were admin-
istered, followed by ﬁve years of daily tamoxifen therapy. In 2005
she had been diagnosed with right breast cancer and was treated
with modiﬁed radical mastectomy. Pathology revealed inﬁltrating
ductal carcinoma of pT2N1M0, which was estrogen receptor posi-
tive, progesterone receptor positive, and HER2-negative. Six cycles
of adjuvant chemotherapy with cyclophosphamide, adriamycin
plus ﬂuorouracil (CAF) were administered, followed by ﬁve years of
daily Arimidex therapy.
During follow-up, the patient complained of gradually blurred
vision several months prior to admission, and bitemporal hemi-
anopsia was noted after her physical examination. Laboratory
investigation ﬁndings were consistent with the diagnosis of anterior
hypopituitarism, as noted in Table 1. The patient's follicle stimulation
and luteinizing hormone level was decreased. Magnetic resonance
imaging (MRI) of the patient's brain showed a lobulated mass
measuring 2.18*4.50 cm lesion involving the pituitary fossa with
suprasellar extension, and compression of the optic chiasma (Fig. 1).
There was inferior extension, causing destruction to the sella ﬂoor
and to the sphenoid sinus. Thereafter, we had a neurosurgeon
perform a surgical tumor removal via trans-sphenoidal route.
Pathologic reports indicated mucinous carcinoma of breastElsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Laboratory value of the patient.
Laboratory tests Value Normal value
Prolactin (ng/mL) 13.47 2e13
LH (mIU/mL) 5.48(L) 10.8e61
FSH (mIU/mL) 25.47(L) 35e151
HGH (ng/mL) 0.09 <10.7
ACTH (pg/mL) 24.7 5e77
Cortisol (ug/dL) 9.41 2.21e5.5
TSH(IU/mL) 0.77 0.25e4
T3 (ng/dL) 125.3 78e182
T4 (ng/dL) 9.75 4.5e12
LH: luteinizing hormone, FSH: follicle-stimulating hormone, HGH: human growth
hormone, ACTH: Adrenocorticotropic hormone, TSH: Thyroid-stimulating hormone,
T3:triiodothyronine, T4:thyroxine, L:low.
Fig. 1. T1-weighted magnetic resonance imaging. Post contrast sagittal image revealed
lobulated enhancing mass (2.18*4.50 cm) involving the pituitary fossa with suprasellar
extension causing optic chiasm compression.
Fig. 2. Hematoxylin and eosin stain (A)40X (B)200X. Microscopically, the sections reveal c
features of metastatic mucinous carcinoma.
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Staging evaluation with PET scan revealed solitary pituitary metas-
tasis, and brain radiation therapy was applied following surgery.
During the months of follow-up, no recurrent sellar mass was
observed. Patient was subsequently placed on endocrine therapy
with femara and survived without relapse for over two years.3. Discussion
Pituitary metastasis is an unusual event of cancer progression,
representing only 1% of pituitary lesions.4 More typically, breast
and lung cancer are the most common primary neoplasm metas-
tasizing to the pituitary in women and men, respectively.2,4,5 Pi-
tuitary metastases more commonly affect the posterior lobe and
the infundibulum than the anterior lobe.5 The predilection for
posterior metastases may stem from the posterior lobe's richer
systemic blood supply via the hypophyseal artery, whereas the
anterior lobe is mainly supplied by the hypophyseal portal system.6
The most common symptom of pituitary metastasis seems to be
diabetes insipidus, reﬂecting a predominance of metastasis to the
posterior lobe.4 Visual impairment resulting from optic chiasm
compression seems to be the second most common pre-
sentation.6e9 However, in a series of 52 patients with pituitary
metastasis, Heshmati et al found that visual impairment was more
common than diabetes insipidus.1 In our case, the patient's initial
presentation was of visual ﬁeld defect with bitemporal hemi-
anopsia. There was no polydipsia, and polyuria presented as the
manifestation of diabetes insipidus.
Diagnosis of pituitary metastasis could be missed by medical
practitioners because most patients who developed pituitary
metastasis are clinically asymptomatic. Patientsmay have signs and
symptoms of nausea, vomiting, fatigue, and weight loss, which
could also be viewed as pan-hypopituitarism, and also be easily
attributed to the side effects of chemotherapy received or the pri-
mary malignancy.4 It can be difﬁcult to diagnose pituitary metas-
tases because the symptoms are nonspeciﬁc and the radiological
differences from primary tumors are trivial.4 As imaging techniques
have evolved, CT had provided the capability to identify pituitary
masses; however, these images are still incapable of enabling reli-
able differentiation between benign and malignant masses. MRI
has perhaps provided a greater possibility of differentiating benign
from malignant disease. But there is no deﬁnite criterion forlusters of neoplastic cells ﬂoating in extracellular mucin pool that is compatible with
Fig. 3. Immunohistochemistry stain (A) ER positive (B) PR positive (C) HER2/neu negative (D) GCDFP-15 positive, a breast carcinoma marker.
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bear inmind the additional historical information that could lead to
a reasonable suspicion of pituitary metastasis,10 such as rapid onset
and progression of symptom, unsuccessful treatment with
bromocriptine, increased age and history of malignancy.
In cases of pituitarymetastasis from breast cancer, most patients
are elderly and have clinical and/or radiologic evidence of wide-
spread disease. Such metastasis is primarily to the lymph nodes,
lung and bone, at the time they are diagnosed with pituitary
metastasis.2,3 However, the present case showed solitary pituitary
metastasis from breast cancer, and there was no evidence of wide
spread disease except existing pituitary metastasis.
Treatment is basically palliative, and depends on the symptoms
and the extent of the systemic disease.9,11e13 It ranges from surgical
removal, radiation surgery, or systemic chemotherapy, focusing on
the extent of the primary tumor. Surgery and even added local ra-
diation are associated with improved symptom relief but do not
affect survival rate. In our presenting case, transsphenoidal removal
of tumor and radiotherapy improved the patient's symptoms.
However, further systemic therapy including chemotherapy, endo-
crine therapy and targeted therapy may extend the life expectancy.
Overall, patient prognosis is poor and depends on the character
of primary neoplasm. Prior studies indicate that the mean survival
length is 6e7 months.2,12 In one investigation, Morita et al found
that age over 65 years at presentation, and short duration between
initial diagnosis of cancer and pituitary invasion have been related
to a poorer outcome.12 However, patients with a single pituitary
metastasis may have a better outcome. As for our presenting case,
the patient's staging evaluation with PET scan showed a solitary
pituitary metastasis, and she had recurrence-free survival
exceeding two years during follow-up.
This report did have its limitations. First, there was a discrep-
ancy of histology between primary breast cancer (inﬁltrating ductal
carcinoma) and metastatic pituitary tumor (mucinous carcinoma).It is important for us to discuss the reason why this possible
discrepancy occurred. We experienced difﬁculty in retrieving an
earlier specimen of breast tissue to make another pathological re-
view due to prolonged time interval (15yrs between primary cancer
and metastatic event). We nearly concluded that the ﬁrst breast
cancer pathology may be the mixed mucinous breast carcinoma,
which suggests inﬁltrating ductal carcinomawith mucinous part. It
may be the mucinous component which metastasizes to the pitu-
itary gland. However, due to the lack of evidence, we could not
reach such a ﬁnal conclusion. This also remind us the importance of
preservation of tissue. The lack of primary tumor tissue may not
affect the decision of therapeutic management due to the complete
removal of metastatic tumor in this patient. However, retrieval of
the metastatic tumor tissue is not always possible especially in the
circumstance of vital organ metastasis. Further therapy should in
accordance of primary tumor behavior in such scenario. In long
term aspect, primary tumor tissue may supply the resources for
research purpose. In the era of personalized medicine, retention of
individualized tissue may offer the potential clinical beneﬁt if tar-
geted medicine evolved.
4. Conclusions
Pituitary metastasis is a rare event in cancer progression. Due to
improvements in diagnosis and systemic therapy of breast cancer,
pituitary metastasis from breast cancer appears to occur even less
frequently. Metastatic breast cancer is incurable, albeit treatable.
However, timely diagnosis and tailored therapy according to pri-
mary tumor and patient condition can produce an improved
outcome.
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